AMEX:INFU

Stock Analysis Report

Executive Summary

InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has InfuSystem Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.6%

INFU

0.6%

US Healthcare

1.0%

US Market


1 Year Return

101.6%

INFU

-9.4%

US Healthcare

6.7%

US Market

Return vs Industry: INFU exceeded the US Healthcare industry which returned -9.4% over the past year.

Return vs Market: INFU exceeded the US Market which returned 6.7% over the past year.


Share holder returns

INFUIndustryMarket
7 Day1.6%0.6%1.0%
30 Day20.6%-3.3%-1.8%
90 Day38.4%-8.9%-1.8%
1 Year101.6%101.6%-8.0%-9.4%9.1%6.7%
3 Year152.9%152.9%30.0%24.8%46.1%36.6%
5 Year94.3%94.3%60.1%50.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is InfuSystem Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InfuSystem Holdings undervalued based on future cash flows and its price relative to the stock market?

6.28x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: INFU ($6.45) is trading above our estimate of fair value ($0.36)

Significantly Undervalued: INFU is trading above our estimate of fair value.


Price Based on Earnings

PE vs Industry: INFU is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: INFU is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate INFU's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: INFU is overvalued based on its PB Ratio (6.3x) compared to the US Healthcare industry average (2.4x).


Next Steps

Future Growth

How is InfuSystem Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InfuSystem Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has InfuSystem Holdings performed over the past 5 years?

-59.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: INFU is unprofitable, and losses have increased over the past 5 years at a rate of -59.2% per year.

Accelerating Growth: Unable to compare INFU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INFU is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: INFU has a negative Return on Equity (-6.78%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: INFU is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: INFU is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is InfuSystem Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: INFU's short term assets ($17.0M) do not cover its short term liabilities ($20.5M)

Long Term Liabilities: INFU's short term assets (17.0M) do not cover its long term liabilities (31.6M)


Debt to Equity History and Analysis

Debt Level: INFU's debt to equity ratio (165.7%) is considered high

Reducing Debt: INFU's debt to equity ratio has increased from 52.5% to 165.7% over the past 5 years.


Balance Sheet

Inventory Level: INFU has a high level of physical assets or inventory.

Debt Coverage by Assets: INFU's debt is not covered by short term assets (assets are 0.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INFU has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if INFU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is InfuSystem Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate INFU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate INFU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if INFU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INFU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INFU's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of InfuSystem Holdings's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Rich DiIorio (44yo)

1.9yrs

Tenure

US$1,049,317

Compensation

Mr. Richard DiIorio, also known as Rich, joined InfuSystem Holdings Inc. in 2004 and has been the Chief Executive Officer, President and Director at InfuSystem Holdings Inc. since November 15, 2017. Mr. Di ...


CEO Compensation Analysis

Compensation vs. Market: Rich has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

52yo

Average Age

Experienced Management: INFU's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

1.4yrs

Average Tenure

54yo

Average Age

Experienced Board: INFU's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$70,83303 Sep 19
Sansone Advisors, LLC
EntityCompany
Shares14,290
Max PriceUS$4.97
BuyUS$136,93826 Aug 19
Sansone Advisors, LLC
EntityCompany
Shares27,792
Max PriceUS$4.95
BuyUS$80,78420 Aug 19
Sansone Advisors, LLC
EntityCompany
Shares16,300
Max PriceUS$4.96
BuyUS$78,92613 Aug 19
AWM Investment Company Inc.
EntityCompany
Shares16,650
Max PriceUS$4.74
BuyUS$11,35017 Jun 19
Scott Shuda
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares2,500
Max PriceUS$4.54
BuyUS$5,09817 Jun 19
BlueLine Partners LLC
EntityCompany
Shares1,123
Max PriceUS$4.54
BuyUS$4,87317 Jun 19
Meridian OHC LLC
EntityCompany
Shares1,100
Max PriceUS$4.43
BuyUS$49,06522 Mar 19
Imua T Capital Investments, Llc
EntityCompany
Shares11,224
Max PriceUS$4.40
BuyUS$109,03319 Mar 19
Sansone Advisors, LLC
EntityCompany
Shares25,000
Max PriceUS$4.36
BuyUS$16,45813 Mar 19
Richard DiIorio
EntityIndividual
Role
Chief Executive Officer
President
Shares3,900
Max PriceUS$4.22

Ownership Breakdown


Management Team

  • John Haggerty

    Senior Vice President of Biomedical Services & Logistics

    • Tenure: 1.8yrs
  • Thomas Ruiz (61yo)

    Senior Vice President of Sales & Marketing

    • Tenure: 1.8yrs
    • Compensation: US$357.52k
  • Jean Pfeiffer

    Senior Vice President of Strategic Initiatives

    • Tenure: 0yrs
  • Rich DiIorio (44yo)

    President

    • Tenure: 1.9yrs
    • Compensation: US$1.05m
  • Jeannine Sheehan

    Executive VP & Chief Administrative Officer

    • Tenure: 0.4yrs
  • Jeanie Latz

    Corporate Secretary

    • Tenure: 0yrs
  • Greg Schulte (52yo)

    Executive VP & CFO

    • Tenure: 1.5yrs
    • Compensation: US$370.24k
  • Carrie Lachance

    Chief Operating Officer

    • Tenure: 0yrs

Board Members

  • Scott Shuda (54yo)

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: US$84.20k
  • Gregg Lehman (71yo)

    Vice Chairman

    • Tenure: 0.8yrs
    • Compensation: US$128.03k
  • Chris Sansone (44yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$90.16k
  • Darrell Montgomery (58yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$85.19k
  • Rich DiIorio (44yo)

    President

    • Tenure: 1.9yrs
    • Compensation: US$1.05m
  • Paul Gendron

    Director

    • Tenure: 0.4yrs

Company Information

InfuSystem Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InfuSystem Holdings Inc.
  • Ticker: INFU
  • Exchange: AMEX
  • Founded: 2005
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$127.597m
  • Shares outstanding: 19.78m
  • Website: https://www.infusystem.com

Number of Employees


Location

  • InfuSystem Holdings Inc.
  • 31700 Research Park Drive
  • Madison Heights
  • Michigan
  • 48071
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INFUAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2006

Biography

InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 02:07
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)